Gene Expression Profiling Identifies Platelet-Derived Growth Factor as a Diagnostic Molecular Marker for Papillary Thyroid Carcinoma
Gene Expression Profiling Identifies Platelet-Derived Growth Factor as a Diagnostic Molecular Marker for Papillary Thyroid Carcinoma
复制标题
DOI：
10.1158/1078-0432.ccr-0807-03
复制
发表时间：
2004-03
影响因子：
11.5
通讯作者：
Yukiko Yano;N. Uematsu;T. Yashiro;H. Hara;E. Ueno;M. Miwa;G. Tsujimoto;Y. Aiyoshi;K. Uchida
中科院分区：
文献类型：
--
作者：
Yukiko Yano;N. Uematsu;T. Yashiro;H. Hara;E. Ueno;M. Miwa;G. Tsujimoto;Y. Aiyoshi;K. Uchida
目的：癌症诊断和治疗通常基于在恶性组织中以高于正常组织的水平特异性表达的临床相关标志物。我们通过使用cDNA微阵列监测甲状腺乳头状癌（PTC）特异性基因表达来检测PTC的潜在标志物。实验设计：PTC组织，正常甲状腺组织和健康外周血细胞的基因表达谱进行了比较，通过使用人类4000基因cDNA微阵列。免疫组化法检测甲状腺组织中PTC上调基因的蛋白表达。结果：PTC组织中有64个基因相对于正常甲状腺组织和健康外周血细胞过表达。在PTC中表达上调的基因涉及细胞周期调控、DNA损伤反应、血管生成和肿瘤发生。在这些基因中，碱性成纤维细胞生长因子和血小板衍生生长因子被确定为在甲状腺肿瘤中以高水平特异性表达的蛋白质。碱性成纤维细胞生长因子，已被确定为PTC的生物标志物，在54%的PTC病例，67%的滤泡性甲状腺癌和36%的良性甲状腺肿瘤中过表达。血小板衍生生长因子在81%的PTC病例和100%的滤泡癌中过表达，但在正常甲状腺组织和良性甲状腺肿瘤中呈免疫阴性。结论：血小板源性生长因子可能是PTC和滤泡性癌的潜在生物标志物。使用微阵列进行表达谱分析，然后进行免疫组织化学研究，可用于促进癌症分子生物标志物的开发。
Purpose: Cancer diagnostics and therapeutics are often based on clinically relevant markers that are expressed specifically in a malignant tissue at levels higher than in normal tissue. We examined potential markers for papillary thyroid carcinoma (PTC) by monitoring PTC-specific gene expression using cDNA microarray. Experimental Design: Gene expression profiles for PTC tissue, normal thyroid tissue, and healthy peripheral blood cells were compared by use of a human 4000-gene cDNA microarray. Protein expressions of the up-regulated genes in PTC were examined in thyroid tissues by immunohistochemistry. Results: Sixty-four genes were overexpressed in PTC tissue relative to normal thyroid tissue and healthy peripheral blood cells. The genes that were up-regulated in PTC were involved in cell cycle regulation, DNA damage response, angiogenesis, and oncogenesis. Among these genes, basic fibroblast growth factor and platelet-derived growth factor were identified by immunochemical methods as proteins that are specifically expressed at high levels in thyroid neoplasms. Basic fibroblast growth factor, which has been identified as a biomarker for PTC, was overexpressed in 54% of PTC cases, 67% of follicular thyroid carcinomas, and 36% of benign thyroid neoplasms. Platelet-derived growth factor was overexpressed in 81% of PTC cases and 100% of follicular carcinomas, but was immunonegative in normal thyroid tissues and benign thyroid neoplasms. Conclusions: Platelet-derived growth factor may be a potential biomarker for PTC and follicular carcinoma. Expression profile analysis using a microarray followed by immunohistochemical study can be used to facilitate the development of molecular biomarkers for cancer.